Physiomics Regulatory News (PYC)

13 Feb 2008 12:07

Physiomics PLC13 February 2008 Physiomics plc The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 13 February 2008 Physiomics plc ("Physiomics" or "the Company") Physiomics to present on Chronotherapy at the Annual Meeting of American Association of Cancer Research ("AACR") Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, ispleased to announce that it will be participating in the 2008 AACR AnnualMeeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez,will present a development update on the Company's chronotherapy researchprogram, as part of the EU funded TEMPO (Temporal Genomics for TailoredChronotherapeutics) project. The abstract will be published in the 2008Proceeding of the AACR and will be presented in the poster session "Cellular andMolecular Biology 8", scheduled for 1:00 pm on 13 April. More information about the conference may be found at www.aacr.org For further information: Physiomics plc +44 (0)1865 784980 Dr Christophe Chassagnole, COO E-mail: cchassagnole@physiomics-plc.com Grant Thornton Corporate Finance +44 (0)20 7383 5100 Philip Secrett, Colin Aaronson About TEMPO project (LSHG-CT-2006-037543) In 2006 Physiomics has been selected to participate in the TEMPO Project as oneof four Industry partners working closely with four distinguished Europeanacademic research groups. The project is coordinated by INSERM unit directorProf Francis Levi, at Paul Brousse hospital in Villejuif (France). This three year programme is exploring the effect of circadian rhythms (thebody's clock) on changes in cell proliferation and the effectiveness of cancerdrugs and will use this knowledge to optimise treatment. The aim is to optimisetreatment of individual patients taking into account the 24h rhythms generatedby the patient's biological clock. Physiomics is using its cell simulationtechnologies to study the effect of cancer drugs on the cell cycle/circadianclock system behaviour, at the cellular level, the cell population level(virtual Fluorescence-Activated Cell-Sorting experiment) or tissue level(virtual tumour). Using pharmacokinetics simulation in connection withpharmacodynamics profile, Physiomics will help establish one or morephysiological relevant drug regimes and delivery schedules. Physiomics will receive approximately £169,000 (€252,650) of matched fundingover the three year period and if successful will share in 3 to 5 newtherapeutic schedules according to the patient profiles for 2 main drug classesagainst cancer and more specifically colorectal cancer. TEMPO develops toolsthat will enable to select the best administration schedule for anti-cancerdrugs, taking into account the genes expression profile of the patient. Undertemporal control of the drug administration, the efficacy as well as thetoxicity will be controlled in an optimised manner. For further information, please visit www.chrono-tempo.org About Physiomics plc Physiomics plc (AIM:PYC) is a computational systems biology services companyapplying simulations of cell behaviour to drug development to reduce the highattrition rates of clinical trials. As 80-90 per cent of all clinical drugcandidates fail to reach the market, estimates1 show that an overall ten percent improvement in success rates could reduce the cost of one drug'sdevelopment by as much as $242 million, from the current estimate of around $800million. Physiomics develops computational systems biology models to predict andunderstand cancer drug efficacy from pre-clinical research to clinicaldevelopment. Physiomics has created detailed mathematical models incorporatingmost important molecular events taking place during the human cell cycle andapoptosis processes. Physiomics developed SystemCell(R) technology, amulti-cellular environment software, which enables the simulation of populationof "virtual cells". Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in2004. For further information, please visit www.physiomics-plc.com SystemCell(R) is a registered trademark of Physiomics plc 1Tufts Centre Impact Report 2002 This information is provided by RNS The company news service from the London Stock Exchange